Omics approaches in pancreatic adenocarcinoma
Palabras clave : 
Pancreatic adenocarcinoma
ctDNA
Proteomic
Genomic
Metabolomic
Lipidomic
FFPE
Tissue
Body fluids
Fecha de publicación : 
2019
Editorial : 
MDPI AG
ISSN : 
2072-6694
Nota: 
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Cita: 
Gonzalez, I. (Iranzu); Viudez, A. (A.); Goñi, S. (Saioa); et al. "Omics approaches in pancreatic adenocarcinoma". Cancers. 11 (8), 2019, 1052
Resumen
Pancreatic ductal adenocarcinoma, which represents 80% of pancreatic cancers, is mainly diagnosed when treatment with curative intent is not possible. Consequently, the overall five-year survival rate is extremely dismal—around 5% to 7%. In addition, pancreatic cancer is expected to become the second leading cause of cancer-related death by 2030. Therefore, advances in screening, prevention and treatment are urgently needed. Fortunately, a wide range of approaches could help shed light in this area. Beyond the use of cytological or histological samples focusing in diagnosis, a plethora of new approaches are currently being used for a deeper characterization of pancreatic ductal adenocarcinoma, including genetic, epigenetic, and/or proteo-transcriptomic techniques. Accordingly, the development of new analytical technologies using body fluids (blood, bile, urine, etc.) to analyze tumor derived molecules has become a priority in pancreatic ductal adenocarcinoma due to the hard accessibility to tumor samples. These types of technologies will lead us to improve the outcome of pancreatic ductal adenocarcinoma patients.

Ficheros en este ítem:
Vista previa
Fichero
cancers-11-01052-v2.pdf
Descripción
Tamaño
884.09 kB
Formato
Adobe PDF


Estadísticas e impacto

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.